ONCAP Completes Investment in Biomerics, Merger with Precision Concepts Medical, and Significant Distribution for ONCAP IV
24 Juillet 2023 - 2:00PM
ONCAP today announced it has closed a significant investment into
Biomerics and provided a material realization for investors in
Precision Concepts including ONCAP IV. As part of the transaction,
Biomerics has merged with the medical business of ONCAP IV’s
current portfolio company, Precision Concepts (“Precision Concepts
Medical”) including Precision Concepts Group of Winston-Salem, NC,
which was acquired from the Marino family in April 2023. This
investment has been made in partnership with Biomerics’ founder and
CEO Travis Sessions, current Biomerics shareholder Wasatch Equity
Partners, and the Marino family. Following this transaction,
Precision Concepts will become a stand-alone pure-play consumer
packaging company with a dedicated focus from the existing
management team on growing both organically and through mergers and
acquisitions (M&A).
The investment in Biomerics was made by a
combination of ONCAP IV, ONCAP V and co-investors. With the
completion of this transaction, Biomerics is the second investment
for ONCAP V alongside Right At School, which closed earlier this
month. Proceeds to Precision Concepts were used to repay debt and
provide a significant distribution to shareholders, including ONCAP
IV.
Following this transaction, Biomerics has over
1.2 million square feet of manufacturing space across 13 locations
making it one of the Top 10 interventional contract development and
manufacturing organizations globally. Biomerics supplies 22 of the
top 35 medical device OEMs and is strategically focused on high
growth end markets including structural heart, electrophysiology,
robotic surgery, cardiovascular disease, and endoscopy. The merger
furthers Biomerics’ fully integrated capability set and positions
it to best serve its OEM customers. Going forward, Biomerics will
be well-capitalized with significant capacity to continue to pursue
strategic M&A.
The Precision Concepts management team, led by
CEO Ray Grupinski, will continue to operate the consumer packaging
business, which possesses strong EBITDA margins and an attractive
growth profile. We believe this transaction helps to simplify and
focus the remaining Precision Concepts business, better positioning
it for a successful exit in the future.
About ONCAPONCAP is the
mid-market private equity platform of Onex. In partnership with
operating company management teams, ONCAP invests in and builds
value in North American headquartered small- and medium-sized
businesses that are market leaders and possess meaningful growth
potential. For more information on ONCAP, visit its website
at www.oncap.com.
Onex is an investor and asset manager that
invests capital on behalf of Onex shareholders and clients across
the globe. Formed in 1984, we have a long track record of creating
value for our clients and shareholders. Our investors include a
broad range of global clients, including public and private pension
plans, sovereign wealth funds, insurance companies and family
offices. In total, Onex has $51.1 billion in assets under
management, of which $7.8 billion is Onex’ own investing
capital. With offices in Toronto, New York, New Jersey, Boston and
London, Onex and its experienced management teams are collectively
the largest investors across Onex’ platforms.
About BiomericsFounded in 1994,
Biomerics is a leading medical device contract manufacturer serving
the interventional device market. Trusted as a vertically
integrated partner, Biomerics provides design and development
services, technology transfer manufacturing services, and contract
manufacturing services for medical device components,
subassemblies, and finished medical devices. Biomerics operates
eight locations in the United States, Ireland, and Costa Rica.
Biomerics is industry leader in materials, interventional medical
plastics, complex extrusion, micromachining of metals and polymers,
laser processing, balloons & balloon catheters, advanced
catheters & steerables, image guided intervention, and finished
device assembly. In addition to operating under a certified ISO
13485:2016 quality system, Biomerics is FDA registered and
compliant with FDA 21 CFR Part 820.
About Precision ConceptsBased
in Mooresville, North Carolina, Precision Concepts is a diversified
manufacturer of finished medical devices and specialty rigid
packaging solutions (sticks, jars, vials, closures, spouts,
bottles, tubes) serving the medical, pharmaceutical, personal care,
food and beverage and nutraceutical industries. The company has
~1,700 employees with twelve manufacturing facilities located in
Canada, the United States, Costa Rica, and the Dominican
Republic.
Forward-Looking StatementsThis
press release may contain, without limitation, statements
concerning possible or assumed future operations, performance or
results preceded by, followed by or that include words such as
“believes”, “expects”, “potential”, “anticipates”, “estimates”,
“intends”, “plans” and words of similar connotation, which would
constitute forward-looking statements. Forward-looking statements
are not guarantees. The reader should not place undue reliance on
forward-looking statements and information because they involve
significant and diverse risks and uncertainties that may cause
actual operations, performance or results to be materially
different from those indicated in these forward-looking statements.
Except as may be required by Canadian securities law, Onex is under
no obligation to update any forward-looking statements contained
herein should material facts change due to new information, future
events or other factors. These cautionary statements expressly
qualify all forward-looking statements in this press release.
For
Further
Information:
Onex Jill Homenuk Managing Director – Shareholder
Relations and CommunicationsTel: +1 416.362.7711 |
Zev KormanVice President, Shareholder Relations and
CommunicationsTel: +1 416.362.7711 |
Onex (TSX:ONEX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Onex (TSX:ONEX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025